摘要
外源性肺表面活性物质（pulmonary surfactant，PS）替代治疗在新生儿呼吸窘迫综合征中的应用已经普及，且疗效确定，但是治疗小儿急性呼吸窘迫综合征（acute respiratory distress syndrome，ARDS）的临床观察结果并不一致。早期研究发现PS可改善ARDS患儿的氧合，降低病死率，但近年来的研究显示PS并不能改善ARDS患儿的远期预后。研究结果的不同可能与PS制剂、给药剂量、给药方法、给药时机等有关。目前不推荐在ARDS治疗中常规使用PS。
Exogenous surfactant replacement has been successfully achieved and become standard therapy in neonatal respiratory distress syndrome, but clinical trials in acute respiratory distress syndrome （ARDS） had mixed re- sults. Early studies show that pulmonary surfactant （PS） administration in ARDS can significantly improve oxygenation and decrease mortality, but in recent years, some clinical trials haven＇t achieve the most substantial benefits to longterm patient outcomes. The inconsistent results of clinical trials may have related to aspects of drug composition, dosing, delivery, and timing. At this time, surfactant therapy cannot be recommended as routine therapy in pediatric ARDS.
出处
《中华实用儿科临床杂志》
CSCD
北大核心
2016年第18期1372-1375,共4页
Chinese Journal of Applied Clinical Pediatrics
